

PEOPLE

Jeremy Curnock Cook, director of International Biotechnology Trust plc, has been elected chairman of the board of Targeted Genetics (Seattle), a newly created position. Mr. Curnock Cook currently serves as director of Rothschild Asset Management Ltd.

Idun Pharmaceuticals (La Jolla, CA) has announced the appointment of **Stanley T. Crooke**, chairman and CEO of Isis Pharmaceuticals, to a new seat on its board of directors. Idun also announced three promotions within senior management: **Lawrence C. Fritz** to executive vice president of research; **Donald S. Karanewsky** to vice president, drug development; and **Kevin J. Tomaselli** to vice president, science and technology. Dr. Fritz, formerly vice president of research and development, is a cofounder and member of the board of Idun. Dr. Karanewsky was previously director of chemistry. Dr. Tomaselli was previously director of cell biology.

Ligand Pharmaceuticals (San Diego) has announced the appointment of **Philip A. Duffy** to the newly created position of vice president, technical operations. Mr. Duffy

most recently served as vice president, product supply for Schein Bayer Pharmaceutical Services.

Paul J. England has been named vice president, discovery operations of Aurora Biosciences (San Diego). Dr. England joins Aurora after 13 years at SmithKline Beecham, where he served most recently as vice president, molecular screening technologies, with worldwide responsibility for high-throughput screening. Aurora has also announced the appointment of **Tad Hurst** to vice president, pharmacoinformatics. Dr. Hurst was formerly at Tripos, where he served as vice president, core software research and development.

Human Genome Sciences (HGS; Rockville, MD) has announced the promotions of **Michael R. Fannon** to the newly created position of vice president and chief information officer and **Reiner L. Gentz** to the newly created position of vice president, protein development. Dr. Gentz joined HGS in 1993 as director of protein expression and purification. Mr. Fannon joined HGS in 1994 as director of bioinformatics. In addition, **Jürgen Drews**,

recently retired president of global research for Hoffmann-LaRoche, has been appointed a member of HGS's board of directors and of its executive committee. Dr. Drews' other board memberships include Protein Design Labs, MorphoSys GmbH, and Genomics Pharmaceutical.

Cytel Corporation (San Diego) has named **Jennifer L. Lorenzen** to the position of vice president of business development and **Edward C. "Ned" Hall** to vice president, CFO. Ms. Lorenzen formerly held the position of vice president and director of therapeutic development at Cytel. Mr. Hall joins Cytel from Medical Device Technologies, where he held the position of CFO.

Immunex Corp. (Seattle) has announced its newest member of the board, **Joseph M. Mahady**. Mr. Mahady is president of Wyeth-Ayerst North America, a division of American Home Products.

Endorex Corporation (Chicago) has announced that **Steven Thornton**, executive vice president of commercial development for Elan Pharmaceutical Technologies, has been named to its board of directors. Elan received the right to appoint a representative to the Endorex board as part of a recent joint venture with Endorex.

PFANSTIEHL

You start with a process.
Now it's time to develop it.

That's where we come in. When it's time to put the pieces together, it's time to call on Pfanstiehl. Consider us your experienced and confidential partners in your process R&D. We are capable of carrying out the production processes you need from bench scale up through pilot and finally bulk production. Our present customers are our best proof of performance. Give us a call and let's discuss where we can productively fit into your picture. Request information.

PFANSTIEHL LABORATORIES, INC.
The source for carbohydrate chemistry

1219 Glen Rock Avenue / Waukegan, IL 60085-0439
847/623-0370 • Toll Free: 1-800/383-0126 • FAX: 847/623-9173


International: Pfanstiehl (Europe) Ltd.
+44 (0) 1606.331825 • FAX: +44 (0) 1606.331826

<http://www.pfanstiehl.com> e-mail: info@pfanstiehl.com



Pf

MAKING THINGS WORK



Richard J. Walsh has been appointed senior vice president, marketing and business development for Pharmacoepia, Inc. (Princeton, NJ). Prior to joining Pharmacoepia, Mr. Walsh served as vice president, marketing and commercial development at Cytogen Corp.

VIMRX Pharmaceuticals (Wilmington, DE) has named **William Wong** vice president, business development. Dr. Wong most recently served as executive director of Intracel Corp.

LIDAK Pharmaceuticals (La Jolla, CA) has announced that **Gerald J. Yakatan** has been appointed to the board of directors of the company. Dr. Yakatan was appointed to fill the vacancy created by the recent resignation of Mr. Daniel J. Paracka, who resigned from the board in January. Dr. Yakatan has served as vice president of drug development for LIDAK on a half-time basis since July 1995. Dr. Yakatan also serves as president and CEO of IriSys Research and Development.